(A) "Communication between a
pharmacist and physician acting under a consult agreement," as used in division
(B)(6) of section 4729.39 of the Revised Code, means any of the
following:
(1) Electronic mail that confirms
delivery;
(2) Interoperable electronic medical
records system;
(3) Facsimile that confirms
delivery;
(4) Electronic prescribing
system;
(5) Electronic pharmacy record
system;
(6) Documented verbal communication;
or
(7) Any other method of documented
notification as outlined in the consult agreement between the pharmacist and
physician.
(A)
"Certified nurse practitioner," "certified
nurse-midwife," "clinical nurse specialist," and "standard care arrangement"
have the same meanings as in section
4723.01 of the Revised
Code.
(B)
"Collaborating physician" means a physician who has
entered into a standard care arrangement with a clinical nurse specialist,
certified nurse-midwife, or certified nurse practitioner.
(C)
"Communication
between a pharmacist and practitioner acting under a consult agreement," as
used in division (D)(6) of section
4729.39 of the Revised Code,
means any of the following:
(1)
Electronic mail that confirms delivery;
(2)
Interoperable
electronic medical records system;
(3)
Facsimile that
confirms delivery;
(4)
Electronic prescribing system;
(5)
Electronic
pharmacy record system;
(6)
Documented verbal communication; or
(7)
Any other method
of documented notification as outlined in the consult agreement between the
pharmacist and practitioner.
(B)(D) "Comorbid disease,"
as used in division (B)(3)(a)
(D)(3)(a) of section
4729.39 of the Revised Code,
means an additional disease that co-occurs with a primary disease. A comorbid
disease may be related to or occur independently of the primary
disease.
(C)(E)
(1) "Communicated" as used in division
(B)(4)
(D)(4)
of section
4729.39 of the Revised Code,
means consent shall be obtained from each individual patient participating in a
consult agreement. With the exception of inpatient management of patient care
at an institutional facility, consent shall be obtained prior to a pharmacist
managing a patient's drug therapy and shall communicate all of the following:
(a) A pharmacist may be utilized in the
management of the patient's care; and
(b) The patient's or an individual authorized
to act on behalf of a patient's right to elect to participate in and withdraw
from the consult agreement.
(2) Consent as required in paragraph
(C)(1)
(E)(1)
of this rule may be obtained as a part of the patient's initial consent to
treatment.
(D)(F) "Consult agreement"
means an agreement that has been entered into pursuant to section
4729.39 of the Revised
Code.
(E)(G) "Institutional
facility" has the same meaning as defined in agency 4729 of the Administrative
Code.
(F)(H) "Managing
pharmacist" means a pharmacist managing a patient's drug therapy pursuant to a
consult agreement.
(I)
"Physician" means an individual authorized under
Chapter 4731. of the Revised Code to practice medicine and surgery or
osteopathic medicine and surgery.
(J)
"Physician
assistant" means an individual who is licensed to practice as a physician
assistant under Chapter 4730. of the Revised Code, holds a valid prescriber
number issued by the state medical board, and has been granted
physician-delegated prescriptive authority.
(G)(K)
(1) "Positive identification" means a method
of identifying a person that does not rely on the use of a private personal
identifier such as a password, but must use a secure means of identification
that includes any of the following:
(a) A
manual signature on a hard copy record;
(b) A magnetic card reader;
(c) A bar code reader;
(d) A biometric method;
(e) A proximity badge reader;
(f) A board approved system of randomly
generated personal questions;
(g) A
printout of every transaction that is verified and manually signed within a
reasonable period of time by the individual who performed the action requiring
positive identification. The printout must be maintained for three years and
made readily retrievable; or
(h)
Other effective methods for identifying individuals that have been approved by
the board.
(2) A method
relying on a magnetic card reader, a bar code reader, a proximity badge reader,
or randomly generated questions for identification must also include a private
personal identifier, such as a password, for entry into a secure mechanical or
electronic system.
(L)
"Practitioner" means any of the following:
(1)
Physician;
(2)
Physician
assistant;
(3)
Clinical nurse specialist, certified nurse-midwife, or
certified nurse practitioner.
(H)(M) "Primary
disease," as used in division (B)(3)(a)
(D)(3)(a) of section
4729.39 of the Revised Code,
means a disease that arises spontaneously and is not associated with or caused
by a previous disease, injury, or event, but that may lead to a comorbid
disease.
(I)(N) "OARRS report"
means a report of information related to a specific person generated by the
drug database established and maintained pursuant to section
4729.75 of the Revised
Code.
(J)(O) "Readily
retrievable" means that records maintained in accordance with this chapter
shall be kept in such a manner that, upon request, they can be produced for
review no later than three business days to an agent, officer or inspector of
the board.
(P)
"Supervising physician" means a physician who has
entered into a supervision agreement with a physician assistant under section
4730.19 of the Revised
Code.
(K)(Q) "Training and
experience related to the particular diagnosis for which drug therapy is
prescribed," as used in division
(A)(3)
(C)(3) of section
4729.39 of the Revised Code,
means an Ohio licensed pharmacist whose license is in good standing and who
meets the training and experience criteria specified in paragraph (A)(1)(k) of
rule
4729:1-6-02 of the
Administrative Code.
(L)(R) "Written notice,"
as used in division
(B)(2)(b)
(D)(2)(b) of section
4729.39 of the Revised Code,
means one of the following methods that is capable of confirming delivery of
the required written notice:
(1) Electronic
mail;
(2) Interoperable electronic
medical records system;
(3)
Facsimile;
(4) Electronic
prescribing system;
(5) Electronic
pharmacy record system;
(6) Any
other method in writing that provides notice in a timely manner; or
(7) Any other method of notification as
outlined in the consult agreement that might reasonably be expected to allow
for the confirmed transmission of the written notification
required.